Log in

NASDAQ:AMTXAemetis Stock Price, Forecast & News

$0.94
+0.13 (+16.05 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.79
Now: $0.94
$0.95
50-Day Range
$0.55
MA: $0.72
$0.87
52-Week Range
$0.37
Now: $0.94
$1.72
Volume874,415 shs
Average Volume182,274 shs
Market Capitalization$19.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Aemetis, Inc. operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products through the conversion of ethanol and biodiesel plants into advanced bio refineries. It owns and operates an ethanol plant in the California Central Valley near Modesto; and a biodiesel plant in Kakinada, India. The company sells biodiesel and refined glycerin to resellers, distributors, and refiners through its sales force and independent sales agents, as well as to brokers who resell the product to end-users. It also produces ethanol; and wet distiller's grains, distiller's corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.
Read More
Aemetis logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryN/A
Current SymbolNASDAQ:AMTX
CUSIPN/A
Phone408-517-3304

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$202 million
Book Value($7.50) per share

Profitability

Net Income$-35,720,000.00

Miscellaneous

Employees152
Market Cap$19.44 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive AMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMTX and its competitors with MarketBeat's FREE daily newsletter.

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

How has Aemetis' stock been impacted by COVID-19 (Coronavirus)?

Aemetis' stock was trading at $0.6511 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMTX shares have increased by 44.4% and is now trading at $0.94. View which stocks have been most impacted by Coronavirus.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aemetis.

How were Aemetis' earnings last quarter?

Aemetis Inc (NASDAQ:AMTX) released its earnings results on Thursday, May, 14th. The specialty chemicals company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.24. The specialty chemicals company earned $39.48 million during the quarter. View Aemetis' earnings history.

Has Aemetis been receiving favorable news coverage?

Media stories about AMTX stock have been trending very negative on Saturday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aemetis earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned news stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAemetis.

Are investors shorting Aemetis?

Aemetis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 12,700 shares, an increase of 81.4% from the April 30th total of 7,000 shares. Based on an average daily trading volume, of 938,200 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company's shares are sold short. View Aemetis' Current Options Chain.

Who are some of Aemetis' key competitors?

What other stocks do shareholders of Aemetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Pennsylvania R.E.I.T. (PEI), Tilly's (TLYS), AMC Entertainment (AMC), Chesapeake Energy (CHK), Great Panther Mining (GPL), Zosano Pharma (ZSAN), DHT (DHT) and Enerplus (ERF).

Who are Aemetis' key executives?

Aemetis' management team includes the following people:
  • Mr. Eric A. McAfee, Co-Founder, Exec. Chairman, CEO & Pres (Age 56)
  • Mr. Todd A. Waltz, Exec. VP, CFO & Sec. (Age 58)
  • Mr. Andrew B. Foster, Exec. VP & COO (Age 54)
  • Mr. Sanjeev Gupta, Exec. VP & MD, Chairman and Pres of Universal Biofuels Pvt. Ltd. (Age 59)

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $0.94.

How big of a company is Aemetis?

Aemetis has a market capitalization of $19.44 million and generates $202 million in revenue each year. Aemetis employs 152 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at 408-517-3304 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.